Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.

@article{Kottke2009ImprovedSD,
  title={Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.},
  author={Timothy J. Kottke and Jill M Thompson and Rosa Mar{\'i}a D{\'i}az and Jos{\'e} Zago Pulido and Candice L Willmon and Matthew C. Coffey and Peter Selby and Alan M Melcher and Kevin Harrington and Richard G. Vile},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2009},
  volume={15 2},
  pages={561-9}
}
PURPOSE The goals of this study were (a) to investigate whether preconditioning of immunocompetent mice with PC-61-mediated regulatory T-cell (Treg) depletion and interleukin-2 (IL-2) would enhance systemic delivery of reovirus into subcutaneous tumors and (b) to test whether cyclophosphamide (CPA), which is clinically approved, could mimic PC-61 for modification of Treg activity for translation into the next generation of clinical trials for intravenous delivery of reovirus. EXPERIMENTAL… CONTINUE READING